New oral anticoagulants for the prevention of thromboembolic complications in atrial fibrillation: A single centre experience

Kardiologia Polska

Volumn 73, Issue 2, 2015, Pages 85-93

  Gorczyca Michta, Iwona ^a   Wozakowska Kapłon, Beata ^a,b  

^a Swietokrzyskie Centre of Cardiology   (Poland)

^b JAN KOCHANOWSKI UNIVERSITY   (Poland)

Author keywords

Atrial fibrillation; Novel oral anticoagulants; Stroke

Indexed keywords

ANTICOAGULANT AGENT; ANTIVITAMIN K; DABIGATRAN; RIVAROXABAN; FIBRINOLYTIC AGENT; VITAMIN K GROUP;

AGE; AGED; ANEMIA; ANTICOAGULANT THERAPY; ARTICLE; BLEEDING; CARDIOVASCULAR DISEASE ASSESSMENT; CEREBROVASCULAR ACCIDENT; CHA2DS2 VASC SCORE; CONTROLLED STUDY; FEMALE; HASBLED SCORE; HEART ARRHYTHMIA; HEART ATRIUM FIBRILLATION; HOSPITAL DISCHARGE; HOSPITALIZATION; HUMAN; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; PAROXYSMAL ARRHYTHMIA; PRESCRIPTION; PROSPECTIVE STUDY; RURAL AREA; THROMBOEMBOLISM; THROMBOSIS PREVENTION; ANTAGONISTS AND INHIBITORS; ATRIAL FIBRILLATION; COMPLICATION; MIDDLE AGED; POLAND; TREATMENT OUTCOME; VERY ELDERLY;

AGE FACTORS; AGED; AGED, 80 AND OVER; ANTICOAGULANTS; ATRIAL FIBRILLATION; FEMALE; FIBRINOLYTIC AGENTS; HUMANS; MALE; MIDDLE AGED; POLAND; PROSPECTIVE STUDIES; THROMBOEMBOLISM; TREATMENT OUTCOME; VITAMIN K;

EID: 84923170012     PISSN: 00229032     EISSN: 18974279     Source Type: Journal    
DOI: 10.5603/kp.a2014.0168     Document Type: Article

References (20)

1. Estes NAM, Halperin JL, Calkins H et al. ACC/AHA physician consortium 2008 clinical performance measures for adults with nonvalvular atrial fibrillation or atrial flutter. J Am Coll Cardiol, 2008; 51: 865-884.
2. Camm AJ, Kirchhof P, Lip GY et al. Guidelines for the management of atrial Fibrillation The Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J, 2010; 31: 2369-2429.
3. Camm AJ, Lip GY, De Caterina R et al. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Eur Heart J, 2012; 33: 2719-2747.
4. Connolly SJ, Ezekowitz MD, Yusuf S et al.; RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med, 2009; 361: 1139-1151.
5. Patel MR, Mahaffey KW, Garg J et al.; ROCKET AF Investigators. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med, 2011; 365: 883-891.
6. Granger CB, Alexander JH, McMurray JJ et al.; ARISTOTLE Committees and Investigators. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med, 2011; 365: 981-992.
7. Connolly SJ, Eikelboom J, Joyner C et al. AVERROES Steering Committee and Investigators. Apixaban in patients with atrial fibrillation. N Engl J Med, 2011; 364: 806-817.
8. Apostolakis S, Sullivan RM, Olshansky B, Lip GY. Factors affecting quality of anticoagulation control among patients with atrial fibrillation on warfarin: the SAMe-TT2R2 Score. Chest, 2013; 144: 1555-1563.
9. Waldo AL, Becker RC, Tapson VF et al. Hospitalized patients with atrial fibrillation and a high risk of stroke are not being provided with adequate anticoagulation. J Am Coll Cardiol, 2005; 46: 1729-1736.
10. Agarwal S, Bennett D, Smith DJ. Predictors of warfarin use in atrial fibrillation patients in the inpatient setting. Am J Cardiovasc Drugs, 2010; 10: 37-48.
11. Nieuwlaat R, Capucci A, Camm AJ et al. Atrial fibrillation management: a prospective survey in ESC member countries: the Euro Heart Survey on atrial fibrillation. Eur Heart J, 2005; 26: 2422-2434.
12. Nabauer M, Gerth A, Limbourg T et al. The Registry of the German Competence NETwork on Atrial Fibrillation: patient characteristics and initial management. Europace, 2009; 11: 423-434.
13. Kirchhof P, Ammentorp B, Darius H et al. Management of atrial fibrillation in seven European countries after the publication of the 2010 ESC Guidelines on atrial fibrillation: primary results of the PREvention oF thromboembolic events: European Registry in Atrial Fibrillation PREFER AF. Europace, 2014; 16: 6-14.
14. Lip GY, Laroche C, Dan GA et al. A prospective survey in European Society of Cardiology member countries of atrial fibrillation management: baseline results of EuroObservational Research Programme Atrial Fibrillation (EORP-AF) Pilot General Registry. Europace, 2014; 16: 308-319.
15. Kakkar AK, Mueller I, Bassand JP et al. Risk profiles and antithrombotic treatment of patients newly diagnosed with atrial fibrillation at risk of stroke: perspectives from the international, observational, prospective GARFIELD registry. PLoOne, 2013; 8: e63479.
16. Chan PS, Maddox T, Tang F et al. Practice-Level Variation in Warfarin Use Among Outpatients With Atrial Fibrillation (from the NCDR PINNACLE Program). Am J Cardiol, 2011; 108: 1136-1140.
17. Pancholy SB, Sharma PS, Pancholy DS et al. Meta-analysis of gender differences in residual stroke risk and major bleeding in patients with nonvalvular atrial fibrillation treated with oral anticoagulants. Am J Cardiol, 2014; 113: 485-490.
18. Dentali F, Riva N, Crowther M et al. Efficacy and safety of the novel oral anticoagulants in atrial fibrillation: a systematic review and meta-analysis of the literature. Circulation, 2012; 126: 2381-2391.
19. Pruszczyk P, Stpiska J, Banasiak W et al. New oral anticoagulants in the prevention of embolic complications in patients with atrial fibrillation. Polish Cardiac Society, Polish Neurological Society and Working Group on Haemostasis of the Polish Society of Haematologists and Transfusiologists consensus statement. Kardiol Pol, 2012; 70: 979-988.
20. Heidbuchel H, Verhamme P, Alings M et al. European Heart Rhythm Association Practical Guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation. Europace, 2013; 15: 625-651.